Clinical Trials Browser

Phase 1/2 × Adenocarcinoma × Androgen Receptor Antagonists × Clear all

NCT02987829 2021-04-23

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Phase 1/2 Completed

72 enrolled 19 charts

Adenocarcinoma